{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:48:10Z","timestamp":1770745690584,"version":"3.49.0"},"reference-count":20,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2016,8,24]],"date-time":"2016-08-24T00:00:00Z","timestamp":1471996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2016,10]]},"abstract":"\n Aim<\/jats:title>\n \n To assess the effect of empagliflozin on cardiovascular (\n CV<\/jats:styled-content>\n ) risk in patients with type 2 diabetes (\n T2DM<\/jats:styled-content>\n ) through a meta\u2010analysis of data from eight placebo\u2010controlled trials.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Data were analysed from eight randomized placebo\u2010controlled trials undertaken to investigate the efficacy and safety of empagliflozin 10 and 25\u2009mg once daily in patients with\n T2DM<\/jats:styled-content>\n , comprising patients at low\/medium and high\n CV<\/jats:styled-content>\n risk. Suspected\n CV<\/jats:styled-content>\n events were prospectively adjudicated. The empagliflozin 10 and 25\u2009mg groups were pooled for the primary analysis. The primary endpoint was a composite of\n CV<\/jats:styled-content>\n death, non\u2010fatal myocardial infarction (\n MI<\/jats:styled-content>\n ), non\u2010fatal stroke and hospitalization for unstable angina [4\u2010point major adverse\n CV<\/jats:styled-content>\n events (\n MACE<\/jats:styled-content>\n )]. The secondary endpoint was a composite of\n CV<\/jats:styled-content>\n death, non\u2010fatal\n MI<\/jats:styled-content>\n and non\u2010fatal stroke (3\u2010point\n MACE<\/jats:styled-content>\n ). Risk estimates were calculated using\n C<\/jats:styled-content>\n ox regression analysis.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 3835 patients received placebo and 7457 received empagliflozin. Total exposure was 7448.3\u2009years for placebo and 15482.1\u2009years for empagliflozin. Four\u2010point\n MACE<\/jats:styled-content>\n occurred in 365 (9.5%) patients receiving placebo and 635 (8.5%) patients receiving empagliflozin [hazard ratio for empagliflozin vs. placebo 0.86 (95%\n CI<\/jats:styled-content>\n 0.76, 0.98)]. Three\u2010point\n MACE<\/jats:styled-content>\n occurred in 307 (8.0%) patients receiving placebo and 522 (7.0%) patients receiving empagliflozin [hazard ratio for empagliflozin vs. placebo 0.84 (95%\n CI<\/jats:styled-content>\n 0.73, 0.96)].\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n In a meta\u2010analysis of data from eight randomized trials involving 11\u200a292 patients with\n T2DM<\/jats:styled-content>\n at low\/medium or high\n CV<\/jats:styled-content>\n risk, empagliflozin was associated with a reduced risk of 4\u2010point\n MACE<\/jats:styled-content>\n and 3\u2010point\n MACE<\/jats:styled-content>\n compared with placebo.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12734","type":"journal-article","created":{"date-parts":[[2016,7,4]],"date-time":"2016-07-04T12:29:45Z","timestamp":1467635385000},"page":"1034-1040","source":"Crossref","is-referenced-by-count":32,"title":["Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta\u2010analysis of data from randomized placebo\u2010controlled trials"],"prefix":"10.1111","volume":"18","author":[{"given":"A.","family":"Salsali","sequence":"first","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Kim","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. J.","family":"Woerle","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U. C.","family":"Broedl","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Hantel","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH Biberach Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,8,24]]},"reference":[{"issue":"1","key":"e_1_2_6_2_1","first-page":"S1","article-title":"Standards of medical care in diabetes\u20132015","volume":"38","author":"American Diabetes Association","year":"2015","journal-title":"Diabetes Care"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.179294"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60484-9"},{"key":"e_1_2_6_5_1","unstructured":"Boehringer Ingelheim.Jardiance\u00ae (empagliflozin) tablets prescribing information.2015.http:\/\/bidocs.boehringer\u2010ingelheim.com\/BIWebAccess\/ViewServlet.ser?docBase=renetnt&folderPath=\/Prescribing+Information\/PIs\/Jardiance\/jardiance.pdf. Accessed June 12 2015."},{"key":"e_1_2_6_6_1","unstructured":"Boehringer Ingelheim.Jardiance\u00ae (empagliflozin) summary of product characteristics.2015.http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002677\/human_med_001764.jsp&mid=WC0b01ac058001d124. Accessed June 12 2015."},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70084-6"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2105"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2673"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12188"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12503"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-3055"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70208-0"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1096"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv728"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-13-28"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005081"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12572"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-016-0356-y"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)00052-8"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12734","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.12734","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.12734","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12734","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:33:01Z","timestamp":1761867181000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,24]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1111\/dom.12734"],"URL":"https:\/\/doi.org\/10.1111\/dom.12734","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,24]]}}}